Workflow
高盛英国今日:公用事业新时代 阿斯利康 宏观 全球 企业对接:公用事业新时代:本土、防御性且不断增长
Goldman Sachs·2025-05-30 04:30

Investment Rating - The report provides a "Buy" rating for AstraZeneca, indicating strong confidence in its growth potential, particularly with the SERD class breast cancer therapy [2]. Core Insights - The utility sector is entering a new era characterized by localized and defensive growth, with electricity demand and revenues on the rise after a 15-year decline. The modernization of the power grid is essential to enhance energy security and meet the demands of renewable energy and data centers [1]. - AstraZeneca's SERD therapy is expected to become a key focus in the upcoming ASCO meeting, with a potential market value exceeding $15 billion by 2035, driven by a patient population of over 5 million globally [2]. - The report highlights SSE and National Grid as top picks in the UK utility sector due to their significant domestic market exposure and positive revenue trajectories [1]. Summary by Sections Utility Sector - The report discusses the necessity for Europe to invest approximately €2 trillion to modernize its electricity systems after years of underinvestment [1]. - Key topics include the recent power outage in Spain and its implications for the utility sector [1]. Pharmaceutical Sector - AstraZeneca's camizestrant is viewed as a critical growth driver, particularly for patients who have undergone endocrine therapy, positioning the company favorably against Roche [2]. - The report anticipates that the complete data presentation for camizestrant could serve as a market catalyst, reflecting its unique positioning and value [2]. Retail and Consumer Goods - The UK clothing market saw a year-on-year growth of 1.4% in the 12 weeks ending April 27, with Zara and M&S leading in sales growth [3]. - In the US, beauty product sales slowed in May, while Beiersdorf outperformed other brands in the skincare segment [3]. Beverage Sector - US beer sales declined by 3.7% over a 12-week period, while the spirits market saw a 3.8% drop, with ABI and STZ receiving a buy rating for gaining market share [4][5].